GARDEN CITY, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $67.42, a high estimate of $80.00, and a low estimate of $55.00. Observing a ...